181 related articles for article (PubMed ID: 20824721)
21. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
22. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
23. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
24. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
25. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
[TBL] [Abstract][Full Text] [Related]
26. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
28. Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer.
Gong Y; Yang J; Wu W; Liu F; Su A; Li Z; Zhu J; Wei T
PLoS One; 2018; 13(5):e0197007. PubMed ID: 29723302
[TBL] [Abstract][Full Text] [Related]
29. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
30. Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma-Do They Exist?
Szpak-Ulczok S; Pfeifer A; Rusinek D; Oczko-Wojciechowska M; Kowalska M; Tyszkiewicz T; Cieslicka M; Handkiewicz-Junak D; Fujarewicz K; Lange D; Chmielik E; Zembala-Nozynska E; Student S; Kotecka-Blicharz A; Kluczewska-Galka A; Jarzab B; Czarniecka A; Jarzab M; Krajewska J
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32610693
[TBL] [Abstract][Full Text] [Related]
31. Lymph node characteristics for predicting locoregional recurrence of papillary thyroid cancer in adolescents and young adults.
Sun Y; Liu X; Ouyang W; Feng H; Wu J; Chen P; Wang J
Oral Oncol; 2017 Mar; 66():22-27. PubMed ID: 28249644
[TBL] [Abstract][Full Text] [Related]
32. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
33. Clinical features and prognosis of patients with benign thyroid disease accompanied by an incidental papillary carcinoma.
Wang SF; Zhao WH; Wang WB; Teng XD; Teng LS; Ma ZM
Asian Pac J Cancer Prev; 2013; 14(2):707-11. PubMed ID: 23621223
[TBL] [Abstract][Full Text] [Related]
34. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
35. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
36. Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography.
Gong RX; Gong YP; Yang J; Wei T; Li-Ling J; Zhu JQ
Genet Mol Res; 2013 Oct; 12(4):4990-7. PubMed ID: 24301760
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features and outcomes in patients with diffuse sclerosing variant of papillary thyroid carcinoma.
Akaishi J; Sugino K; Kameyama K; Masaki C; Matsuzu K; Suzuki A; Uruno T; Ohkuwa K; Shibuya H; Kitagawa W; Nagahama M; Shimizu K; Ito K
World J Surg; 2015 Jul; 39(7):1728-35. PubMed ID: 25743484
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification.
Tavarelli M; Sarfati J; Chereau N; Tissier F; Golmard JL; Ghander C; Lussey-Lepoutre C; Trésallet C; Menegaux F; Leenhardt L; Buffet C
Thyroid; 2017 Jun; 27(6):778-786. PubMed ID: 28351220
[TBL] [Abstract][Full Text] [Related]
39. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
40. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
